Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: Nat Neurosci. 2011 Nov 20;15(1):64–69. doi: 10.1038/nn.2986

Fig. 4.

Fig. 4

ARN272 produces CB1-dependent antinociception in mice. Intraplantar injection of formalin (5%, 20 μL) elicited two temporally distinct phases of nocifensive behavior in mice: phase I (0–5 min, open bars) and phase II (5–45 min, closed bars). (a) ARN272 (doses in mg-kg−1, i.p.) decreased nocifensive behavior in both phases. (b) The CB1 antagonist AM251 (1 mg-kg−1, i.p.) abolished the antinociceptive effects of ARN272, whereas the CB2 antagonist AM630 and the TRPV1 antagonist AMG9810 did not. (c–f) Intraplantar injection of carrageenan (car) elicited a local inflammatory response in mice. ARN272 (mg-kg−1, i.p.) decreased (c) thermal hyperalgesia (withdrawal latency, in seconds), and (e) edema (volume, in ml). The CB1 antagonist AM251 (1 mg-kg−1, i.p.) suppressed the effects of ARN272 on (d) thermal hyperalgesia and (f) edema. Results are expressed as the mean±SEM of 6 mice per group. *, P<0.05; **, P<0.01; ***, P<0.001 versus vehicle-injected controls; two-way ANOVA followed by Bonferroni's test.